Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
https://doi.org/10.14341/2072-0351-5680
Abstract
Aim.
To study Actovegin efficacy in oxidative stress (OS) correction at diabetic polyneuropathy (DPN) in patients with diabetes mellitus type 2 (DM2)and arterial hypertension (AH).Materials and Methods.
51 patients (24 women and 27 men) aged 53.4?0.7 with the average duration of DM2 5.6?0.2 years, DPN - 4.9?0.2years and AH - 6.0?0.2 years were examined. Daily albuminuria, glomerular filtration rate (GRF) were evaluated, standard methods for diagnosisof DPN were used. 26 patients took Actovegin therapy during 6-8 weeks, the rest 25 patients were in the control group. Parameters of the OS werestudied.
Results.
The increase of total oxidative capacity, the decrease of total antioxidant capacity and the rise of levels of antibodies to oxidated LDL wererevealed in patients with DM2, DPN and AH. Antioxidant and anti-hypoxic effects of 400 mg/day of Actovegin were established in this group of patients.Conclusions. Actovegin impacts oxidative stress parameters and improves the clinical manifestation of diabetic polyneuropathy.
To study Actovegin efficacy in oxidative stress (OS) correction at diabetic polyneuropathy (DPN) in patients with diabetes mellitus type 2 (DM2)and arterial hypertension (AH).Materials and Methods.
51 patients (24 women and 27 men) aged 53.4?0.7 with the average duration of DM2 5.6?0.2 years, DPN - 4.9?0.2years and AH - 6.0?0.2 years were examined. Daily albuminuria, glomerular filtration rate (GRF) were evaluated, standard methods for diagnosisof DPN were used. 26 patients took Actovegin therapy during 6-8 weeks, the rest 25 patients were in the control group. Parameters of the OS werestudied.
Results.
The increase of total oxidative capacity, the decrease of total antioxidant capacity and the rise of levels of antibodies to oxidated LDL wererevealed in patients with DM2, DPN and AH. Antioxidant and anti-hypoxic effects of 400 mg/day of Actovegin were established in this group of patients.Conclusions. Actovegin impacts oxidative stress parameters and improves the clinical manifestation of diabetic polyneuropathy.
About the Authors
Ivan Petrovich Gorshkov
Voronezh State Medical Academy named by N.N. Burdenko, Voronezh
Vladimir Ivanovich Zoloedov
Voronezh State Medical Academy named by N.N. Burdenko, Voronezh
Anna Petrovna Volynkina
Voronezh State Medical Academy named by N.N. Burdenko, Voronezh
References
1. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. - М.: Медиа сфера, 2009. - 103 с.
2. Дедов И.И., Шестакова М.В. Сахарный диабет: Руководство для врачей. - М.: Универсум Паблишинг, 2003. - 455 с.
3. Diabetic Neuropathy: Clinical Management SE / Ed. by A. Veves, R.A. Malik // Humana Press, 2007. - 516 p.
4. Ziegler D., Movsesyan L., Mankovsky B., Gurieva I., Abylaiuly Z., Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients // Diabetes Care. - 2009. - Vol. 32, N 8. - P. 1479-1484.
5. Верткин А.Л. Применение актовегина у больных сахарным диабе- том: Метод. рекомендации. - Москва, 2006. - 31 с.
6. Рекомендации экспертов всероссийского научного общества кар- диологов по диагностике и лечению метаболического синдрома / под ред. проф., д.м.н. И.Е. Чазова. - М.: ВНОК, - 2009. - 32 с.
7. Kaya A., Uzunhasan I., Baskurt M., Ozkan A., Ataoglu E., Okcun B., Yigit Z. Oxidative status and lipid profile in metabolic syndrome: gender differences // Metab. Syndr. Relat. Disord. - 2010. - Vol. 8, № 1. - P. 53-58.
8. Ahmed F.N., Naqvi F.N., Shafiq F. Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus // Ann. N. Y. Acad. Sci. - 2006. - Vol. 1084. - P. 481-489.
9. Alexandraki K., Piperi C., Kalofoutis C., Singh J., Alaveras A., Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines // Annals of the New York Academy of Sciences. - 2006. - Vol. 1084. - P. 89-117.
10. Allen D.A., Yaqoob M.M., Harwood S.M. Mechanisms of high glucoseinduced apoptosis and its relationship to diabetic complications // J. Nutr. Biochem. - 2005. - Vol. 16, № 12. - P. 705-713.
11. Dordević G., Durić S., Apostolskit S., Dordević V., Zivković M. Total antioxidant blood capacity in patients with type 2 diabetes mellitus and distal symmet-rical polyneuropathy // Vojnosanit Pregl. - 2008. - Vol. 65, № 9. - P. 663-669.
12. Figueroa-Romero C., Sadidi M., Feldman E.L. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy // Rev. Endocr. Metab. Disord. - 2008. - Vol. 9, № 4. - P. 301-314.
13. Сыч Ю.П., Зилов А.В. Актовегин: лечение и профилактика осложнений сахарного диабета // Врач. - 2005. - № 3. - С. 56-59.
14. Сыч Ю.П., Зилов А.В. Возможности применения актовегина в лечении сахарного диабета // Проблемы эндокринологии. - 2003. - Т. 49, № 3. - С. 51-53.
15. Опыт клинического применения Актовегина в эндокринологии. Сборник статей. - М.: РКИ Соверо пресс, 2005. - 72 с.
16. Инчина В.И., Смирнов Л.Д., Кокорева Е.В., Морозов М.Ю. Ангиопротекторная активность комбинации этилметилгидроксипиридин су- кцината (мексикора) с актовегином при облитерирующем атеросклерозе артерий нижних конечностей // Регионарное кровообращение и микроциркуляция. - 2007. - Т. 6, № 2. - С. 58-62.
17. Cameron N.E., Cotter M.A. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway // Curr. Drug. Targets. - 2008. - Vol. 9, № 1. - P. 60-67.
18. Vincent A.M., Russell J.W., Low P., Feldman E.L. Oxidative stress in the pa-thogenesis of diabetic neuropathy // Endocr. Rev. - 2004. - Vol. 25, N 4. - P. 612-628.
19. Моргоева Ф.Э., Аметов А.С., Строков И.А. Диабетическая энцефа- лопатия и полиневропатия: терапевтические возможности Актове- гина // Русский медицинский журнал. - 2005. - Т. 13, № 6. - С. 302-304.
20. Pop-Busui R., Sima A., Stevens M. Diabetic neuropathy and oxidative stress // Diabetes Metab Res Rev. - 2006. - Vol. 22, № 4. - P. 257-273.
21. Ziegler D., Sohr C.G., Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy // Diabetes Care. - 2004. - Vol. 27, № 9. - P. 2178-2183.
22. Креминская В.М., Гурьева И.В. Возможность применения Актовегина при поздних осложнениях сахарного диабета // Русский медицин- ский журнал. - 2004. - Т. 12, № 9. - С. 564-567.
23. Kopprasch S., Pietzsch J., Kuhlisch E. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance // Diabetes. - 2002. - Vol. 51. - P. 3102-3106.
24. Cameron N.E., Gibson T.M., Nangle M.R., Cotter M.A. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimen-tal diabetes // Ann. N. Y. Acad. Sci. - 2005. - Vol. 1043. - P. 784-792.
25. Nourooz-Zadeh J., Ziegler D., Sohr C., Betteridge J.D., Knight J., Hothersall J. The use of pholasin as a probe for the determination of plasma total antioxi-dant capacity // Clin. Biochem. - 2006. - Vol. 39, № 1. - P. 55-61.
26. Obrosova I.G. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications // Antioxid Redox Signal. - 2005. - Vol. 7, № 11-12. - P. 1543-1552.
27. Jacob S., Dietze G.J., Machicao F., Kuntz G., Augustin H.J. Improvement of glucose metabolism in patients with type II diabetes after treatment with a hemodialysate // Arzneimittelforschung. - 1996. - Vol. 46. - P. 269-272.
28. Obermaier-Kusser B., Mьhlbacher C., Mushack J., Seffer E., Ermel B., Machicao F., Schmidt F., Hдring H.U. Further evidence for a two-step model of glu-cose-transport regulation. Inositol phosphate oligosaccharides regulate glu-cose-carrier activity // Biochem. J. - 1989. - vol. 261. - P. 699-705.
29. Pavlov O.O. Effect of antihypoxant actovegin on dynamics of markers of the oxygen cascade // Klin. Khir. - 2008. - Vol. 9. - P. 57-59.
30. Kohner E.M., Porta M. Protocols for screening and treatment of diabetic retinopathy in Europe // Eur. J. Ophthalmol. - 1991. - Vol. 1, № 1. - P. 45-54.
31. National Kidney Foundation. KDOQI™ Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.// Am. J. Kidney. Dis. - 2007. - Vol. 49, № 2 (Suppl. 2). P. S1-S180.
32. Bouhassira D., Attal N., Alchaar H., Boureau F., Brochet B., Bruxelle J., Cu-nin G., Fermanian J., Ginies P., Grun-Overdyking A., Jafari-Schluep H., Lan-tйri-Minet M., Laurent B., Mick G., Serrie A., Valade D., Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) // Pain. - 2005. - Vol. 114, № 1-2. - P. 29-36.
33. Dyck P.J. Detection, characterization, and staging of polyneuropathy: assessed in diabetics // Muscle. Nerve. - 1988. - Vol. 11, № 1. - P. 21-32.
34. Thomas P.K. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy / P.K. Thomas // Diabetes. - 1997. - Vol. 46, Suppl. 2. - P. S54-S57.
35. Fontaine R., Fontaine J.L. Diabetic arteritis and gangrene in surgical clinic // Cah. Coll. Med. Hop. Paris. - 1969. - Vol. 10, № 3. - P. 165-179.
36. Оболенский В.Н. Комплексное лечение больных с синдромом диабе- тической стопы // Фарматека. - 2008. - № 8. - С. 49-52.
Review
For citations:
Gorshkov I.P., Zoloedov V.I., Volynkina A.P. Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension. Diabetes mellitus. 2010;13(2):84-89. (In Russ.) https://doi.org/10.14341/2072-0351-5680
Views:
2527
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
